How to buy Omeros Corporation stock | $6.32

Omeros Corporation is a biotechnology business based in the US. Omeros Corporation shares (OMER) are listed on the NASDAQ and all prices are listed in US Dollars. Omeros Corporation employs 277 staff and has a trailing 12-month revenue of around 0.00.

Omeros Corporation stock price (NASDAQ: OMER)

Use our graph to track the performance of OMER stocks over time.

Omeros Corporation shares at a glance

• Key figures

Information last updated 2021-10-24.

Latest market close	$6.32
52-week range	$5.45 - $23.14
50-day moving average	$11.43
200-day moving average	$14.81
Wall St. target price	$35.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.28

Buy Omeros Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Omeros Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Omeros Corporation price performance over time

Historical closes compared with the close of $6.32 from 2021-10-25

1 week (2021-10-20)	-1.25%
1 month (2021-09-27)	-56.50%
3 months (2021-07-27)	-55.80%
6 months (2021-04-27)	-64.99%

1 year (2020-10-26)	-38.16%
2 years (2019-10-25)	-60.33%
3 years (2018-10-26)	16.16
5 years (2016-10-26)	8.16

Omeros Corporation financials

Revenue TTM	$86.6 million
Gross profit TTM	$6.2 million
Return on assets TTM	-65.87%
Return on equity TTM	0%
Profit margin	-160.93%
Book value	$-2.65
Market capitalisation	$405.6 million

TTM: trailing 12 months

Shorting Omeros Corporation shares

There are currently 9.9 million Omeros Corporation shares held short by investors – that's known as Omeros Corporation's "short interest". This figure is 4.9% down from 10.4 million last month.

There are a few different ways that this level of interest in shorting Omeros Corporation shares can be evaluated.

Omeros Corporation's "short interest ratio" (SIR)

Omeros Corporation's "short interest ratio" (SIR) is the quantity of Omeros Corporation shares currently shorted divided by the average quantity of Omeros Corporation shares traded daily (recently around 470809.38989514). Omeros Corporation's SIR currently stands at 20.98. In other words for every 100,000 Omeros Corporation shares traded daily on the market, roughly 20980 shares are currently held short.

However Omeros Corporation's short interest can also be evaluated against the total number of Omeros Corporation shares, or, against the total number of tradable Omeros Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Omeros Corporation's short interest could be expressed as 0.16% of the outstanding shares (for every 100,000 Omeros Corporation shares in existence, roughly 160 shares are currently held short) or 0.1649% of the tradable shares (for every 100,000 tradable Omeros Corporation shares, roughly 165 shares are currently held short).

A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Omeros Corporation.

Find out more about how you can short Omeros Corporation stock.

Omeros Corporation share dividends

We're not expecting Omeros Corporation to pay a dividend over the next 12 months.

Have Omeros Corporation's shares ever split?

Omeros Corporation's shares were split on 1 October 2009.

Omeros Corporation share price volatility

Over the last 12 months, Omeros Corporation's shares have ranged in value from as little as $5.45 up to $23.14. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Omeros Corporation's is 1.1693. This would suggest that Omeros Corporation's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Omeros Corporation overview

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN), atypical hemolytic uremic syndrome (aHUS), and COVID-19; and Phase II clinical trial to treat lupus nephritis and other renal diseases. Its clinical programs also consist of PPAR? (OMS405) to treat opioid and nicotine addiction; PDE7 (OMS527) for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs include G protein-coupled receptor (GPCR) platform, including GPR174, GPR151, GPR161, and other Class A orphan GPCRs for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.

Frequently asked questions

What percentage of Omeros Corporation is owned by insiders or institutions?
Currently 4.128% of Omeros Corporation shares are held by insiders and 52.272% by institutions. How many people work for Omeros Corporation?
Latest data suggests 277 work at Omeros Corporation. When does the fiscal year end for Omeros Corporation?
Omeros Corporation's fiscal year ends in December. Where is Omeros Corporation based?
Omeros Corporation's address is: The Omeros Building, Seattle, WA, United States, 98119 What is Omeros Corporation's ISIN number?
Omeros Corporation's international securities identification number is: US6821431029 What is Omeros Corporation's CUSIP number?
Omeros Corporation's Committee on Uniform Securities Identification Procedures number is: 682143102